Silenseed develops a novel platform for cancer therapies without chemotherapy and radiation, based on its proprietary delivery technology for gene-therapy drugs including siRNA. The company operates at the campus of the Hadassah Medical Center in Jerusalem, in collaboration with the Institutes of Gene Therapy, School of Pharmacology and Minimal Invasive Surgery that provide capabilities for R&D, pre-clinical, GMP, and clinical studies. The company’s prime target is to provide therapy for pancreatic cancer, an incurable disease, reflecting a market estimated at $2B worldwide.